<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02195609</url>
  </required_header>
  <id_info>
    <org_study_id>IP-2013-01</org_study_id>
    <nct_id>NCT02195609</nct_id>
  </id_info>
  <brief_title>Evaluate the Effect of Omega-3 vs Soy Isoflavones in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms</brief_title>
  <acronym>OMEGASI</acronym>
  <official_title>Randomized Open Label Study to Evaluate the Effect of (Omega-3) EPA + Docosahexaenoic Acid (DHA) vs Soy Isoflavones in 100 Postmenopausal Women Between 45-65 Years With Moderate to Severe Vasomotor Symptoms.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Palacios</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ferrer Internacional S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Palacios</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aiming to evaluate changes in vasomotor symptoms in postmenopausal women&#xD;
      treated for 4 months with Omega-3 vs Soy Isoflavones.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-inferiority study of Omega 3 versus Soy Isoflavones, being each patient its own&#xD;
      control from the baseline.&#xD;
&#xD;
      In order to determine the difference observed in the evolution of intensity, frequency and&#xD;
      the total number of hot flashes in 4 months in patients treated with Omega-3 vs Soy&#xD;
      Isoflavones, is planned to include at least 100 patients, 50 per treatment arm.&#xD;
&#xD;
      It si estimated a standar deviation of 0.5%, and a 10% lost follow-up rate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the changes in vasomotor symptoms.</measure>
    <time_frame>0 to 4 months</time_frame>
    <description>To evaluate the changes in vasomotor symptoms in postmenopausal women measured by a hot flushes self-completed diary .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk factors</measure>
    <time_frame>0 and 4 months</time_frame>
    <description>serum cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with treatment</measure>
    <time_frame>at month 1 and 4</time_frame>
    <description>Treatment Satisfaction Questionnaire for Medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood status</measure>
    <time_frame>0, 1 and 4 months</time_frame>
    <description>Hospital Anxiety and Depression Scale (HADS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General health status</measure>
    <time_frame>months 0, 1 and 4</time_frame>
    <description>General health status by Short-Form 36 (SF-36) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rating memory status</measure>
    <time_frame>at 0, 1 and 4 months</time_frame>
    <description>Alteration of the memory test (T@M)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk factors</measure>
    <time_frame>0 amd 4 months</time_frame>
    <description>serum triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk factors</measure>
    <time_frame>0, 1 and 4 months</time_frame>
    <description>Blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk factors</measure>
    <time_frame>0, 1 and 4 months</time_frame>
    <description>Body mass index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk factors</measure>
    <time_frame>0, 1 and 4 months</time_frame>
    <description>abdominal circumference</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Menopause</condition>
  <condition>Hot Flashes</condition>
  <arm_group>
    <arm_group_label>Omega-3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>600 mg (EPA, DHA and Omega-3) twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Soy Isoflavones</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>54.4mg oral twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega-3</intervention_name>
    <description>600 mg oral twice a day</description>
    <arm_group_label>Omega-3</arm_group_label>
    <other_name>Om3gafort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Soy Isoflavones</intervention_name>
    <description>54.4 mg oral twice a day</description>
    <arm_group_label>Soy Isoflavones</arm_group_label>
    <other_name>Flavia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ambulatory and can complete all study procedures, which are able to read, understand&#xD;
             and sign an informed consent and willing to come to the center for study visits.&#xD;
&#xD;
          -  Postmenopausal (≥ 1 year of amenorrhea) or 6 months or more of amenorrhea with&#xD;
             follicle stimulating hormone (FSH) ≥ 40 IU / L.&#xD;
&#xD;
          -  BMI ≥ 18 kg/m2 and ≤ 30 kg/m2&#xD;
&#xD;
          -  Flushing of moderate to severe intensity.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with surgical menopause.&#xD;
&#xD;
          -  Treatment with hormone replacement therapy (HRT) in the 3 months prior to inclusion&#xD;
&#xD;
          -  Uterine bleeding after menopause with undetermined cause in the 12 months prior to&#xD;
             screening.&#xD;
&#xD;
          -  Presence or history of malignancy in the past 5 years.&#xD;
&#xD;
          -  Malabsorption syndrome.&#xD;
&#xD;
          -  Hype or uncontrolled hypothyroidism.&#xD;
&#xD;
          -  Dyslipidemia (LDL-cholesterol&gt; 189 mg / dl or medical criteria) requiring an specific&#xD;
             treatment of proven effectiveness.&#xD;
&#xD;
          -  Chronic renal disease.&#xD;
&#xD;
          -  Uncontrolled or untreated hypertension.&#xD;
&#xD;
          -  Treatment with isoflavones, tibolone, Selective Estrogen Receptors Moderators (SERM´s)&#xD;
             in the past 3 months prior to the testing selection period.&#xD;
&#xD;
          -  Hormonal treatment with androgens, estrogens, progestins, alone or combined oral,&#xD;
             transdermal, vaginal (including promestriene) or implant, in the last 3 months prior&#xD;
             to testing selection period.&#xD;
&#xD;
          -  Patients who receive or require treatment with antidepressants or anticonvulsants&#xD;
&#xD;
          -  Patients with mental illness.&#xD;
&#xD;
          -  History of noncompliance with taking medication.&#xD;
&#xD;
          -  Suspected or abuse of alcohol or other drugs during the 12 months preceding the&#xD;
             selection.&#xD;
&#xD;
          -  Use of any experimental drug or device within 30 days prior to the selection.&#xD;
&#xD;
          -  Any other condition or finding that a judgment of the investigator may jeopardise the&#xD;
             tral conduct according to the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Santiago Palacios, MD</last_name>
    <role>Study Director</role>
    <affiliation>President of the European Foundation Woman and Health,Past President and Honorary Member of the Spanish Menopause Society, President of the Council of Affiliated Menopause Societies (CAMS)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Palacios</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>July 15, 2014</study_first_submitted>
  <study_first_submitted_qc>July 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2014</study_first_posted>
  <last_update_submitted>September 15, 2016</last_update_submitted>
  <last_update_submitted_qc>September 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vasomotor Symptoms Associated With Menopause</keyword>
  <keyword>Menopause</keyword>
  <keyword>Hot Flashes</keyword>
  <keyword>Postmenopausal Women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

